doi:10.3969/j.issn.1004-583X.2025.05.015

Abstract

CLC Number:

Add to citation manager EndNote|Ris|BibTeX

URL: http://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.05.015

http://www.lchc.cn/EN/Y2025/V40/I5/463

References 41

[1]	Li X, Zuo C, Chen C, et al. Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: A prospective cohort study[J]. Int J Cardiol, 2023, 371(10):244-25.
[2]	曹馨瑞, 严思敏, 姚惠敏, 等. 沙库巴曲缬沙坦在心律失常治疗中的研究进展[J]. 中南药学, 2023, 21(3):726-730.
[3]	Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge[J]. Int J Stroke, 2021, 16(2):217-221.
[4]	Chen M, Li C, Liao P, et al. Epidemiology, management and outcomes of atrial fibrillation among 30 million medicare subjects of Shanghai, China from 2015 to 2020[J]. Lancet Reg Health West Pac, 2022,23:100470.
[5]	von Lueder TG, Wang BH, Kompa AR, et al. Angiotensin receptor neprilysin inhibitor lcz696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy[J]. Circ Heart Fail, 2015, 8(1):71-78. doi: 10.1161/CIRCHEARTFAILURE.114.001785 pmid: 25362207
[6]	Li Q, Fang Y, Peng DW, et al. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats[J]. Eur J Pharmacol, 2023, 952:175754.
[7]	Iwamiya S, Ihara K, Furukawa T, et al. Sacubitril/valsartan attenuates atrial conduction disturbance and electrophysiological heterogeneity with ameliorating fibrosis in mice[J]. Front Cardiovasc Med, 2024, 11:1341601.
[8]	Suo Y, Yuan M, Li H, et al. Sacubitril/valsartan improves left atrial and left atrial appendage function in patients with atrial fibrillation and in pressure overload-induced mice[J]. Front Pharmacol, 2019, 10:1285. doi: 10.3389/fphar.2019.01285 pmid: 31736759
[9]	Moon MG, Hwang IC, Lee HJ, et al. Reverse remodeling assessed by leftatrial and ventricular strain reflectstreatment response to sacubitril/valsartan[J]. JACC Cardiovasc Imaging, 2022, 15(9):1525-1541.
[10]	庞志华, 赵伟, 田留, 等. 沙库巴曲缬沙坦对心肌梗死后心力衰竭大鼠的心脏保护机制探讨[J]. 天津医药, 2022, 50(11):1171-1176.
[11]	Guo YH, Yang YQ. Atrial fibrillation: Focus on myocardial connexins and gap junctions[J]. Biology (Basel), 2022, 11(4):489.
[12]	孙昌民, 钟江华. NLRP3炎症小体在心房颤动中的作用机制[J]. 中国心血管病研究, 2024, 22(4):375-380.
[13]	Ajoolabady A, Nattel S, Lip GYH, et al. Inflammasome signaling in atrial fibrillation: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2022, 79(23):2349-2366. doi: 10.1016/j.jacc.2022.03.379 pmid: 35680186
[14]	Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death[J]. Cell Mol Immunol, 2021, 18(9):2114-2127. doi: 10.1038/s41423-021-00740-6 pmid: 34321623
[15]	Li X, Zhu Q, Wang Q, et al. Protection of Sacubitril/valsartan against pathological cardiac remodeling by inhibiting the NLRP3 inflammasome after relief of pressure overload in mice[J]. Cardiovasc Drugs Ther, 2020, 34(5):629-640. doi: 10.1007/s10557-020-06995-x pmid: 32444995
[16]	De Vecchis R, Paccone A, Di Maio M. Upstream therapy for atrial fibrillation prevention: The role of sacubitril/valsartan[J]. Cardiol Res, 2020, 11(4):213-218.
[17]	De Vecchis R, Paccone A, Di Maio M. Favorable effects of sacubitril/valsartan on the peak atrial longitudinal strain in patients with chronic heart failure and a history of one or more episodes of atrial fibrillation: A retrospective cohort study[J]. J Clin Med Res, 2020, 12(2):100-107. doi: 10.14740/jocmr4076 pmid: 32095179
[18]	Badano LP, Kolias TJ, Muraru D, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: A consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging[J]. Eur Heart J Cardiovasc Imaging, 2018, 19(6):591-600. doi: 10.1093/ehjci/jey042 pmid: 29596561
[19]	Hopman LHGA, Bhagirath P, Mulder MJ, et al. Left atrial sphericity in relation to atrial strain and strain rate in atrial fibrillation patients[J]. Int J Cardiovasc Imaging, 2023, 39(9):1753-1763.
[20]	Brás PG, Gonçalves AV, Branco LM, et al. Sacubitril/valsartan improves left atrial and ventricular strain and strain rate in patients with heart failure with reduced ejection fraction[J]. Life (Basel), 2023, 13(4):995.
[21]	成绩, 胡豪畅, 林少沂, 等. 沙库巴曲缬沙坦治疗心血管疾病临床应用研究进展[J]. 浙江医学, 2022, 44(4):441-446.
[22]	Cheng WH, Lugtu IC, Chang SL, et al. Effects of angiotensin receptor-neprilysin inhibitor in arrhythmogenicity following left atrial appendage closure in an animal model[J]. Cardiovasc Drugs Ther, 2021, 35(4):759-768.
[23]	Reilly SN, Jayaram R, Nahar K, et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: Implications for the antiarrhythmic effect of statins[J]. Circulation, 2011, 124(10):1107-1117. doi: 10.1161/CIRCULATIONAHA.111.029223 pmid: 21844076
[24]	Artaç İ, Öˇgün M, Omar T, et al. The importance of nitric oxide and oxidative stress in atrial high-rate episodes in patients with cardiac devices[J]. Turk Kardiyol Dern Ars, 2024, 52(2):81-87. doi: 10.5543/tkda.2023.07433 pmid: 38465533
[25]	徐登月, 于立明, 王辉山. 氧化应激作用于房颤发病机制中的研究现状[J]. 中国临床药理学杂志, 2023, 39(4):583-587.
[26]	王思佳, 赵育洁, 王地, 等. 沙库巴曲/缬沙坦在快速型室性心律失常领域中的研究进展[J]. 中国循证心血管医学杂志, 2023, 15(1):120-122+126.
[27]	Wang Y, Zhou R, Lu C, et al. Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: Meta-analysis[J]. J Am Heart Assoc, 2019, 8(13):e012272.
[28]	Chang PC, Wo HT, Lee HL, et al. Sacubitril/valsartan therapy ameliorates ventricular tachyarrhythmia inducibility in a rabbit myocardial infarction model[J]. J Card Fail, 2020, 26(6):527-537.
[29]	Ge Q, Zhao L, Ren XM, et al. LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis[J]. Exp Biol Med (Maywood), 2019, 244(12):1028-1039. doi: 10.1177/1535370219861283 pmid: 31262190
[30]	Okutucu S, Fatihoglu SG, Sabanoglu C, et al. Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction[J]. Herz, 2021, 46(Suppl 1):69-74. doi: 10.1007/s00059-019-04872-4
[31]	Zhu T, Zhang W, Yang Q, et al. Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation[J]. Front Cardiovasc Med, 2022, 9:1048077.
[32]	Russo V, Bottino R, Rago A, et al. The effect of sacubitril/valsartan on device detected arrhythmias and electrical parameters among dilated cardiomyopathy patients with reduced ejection fraction and implantable cardioverter defibrillator[J]. J Clin Med, 2020, 9(4):1111.
[33]	Guerra F, Pimpini L, Flori M, et al. Sacubitril/valsartan reduces atrial fibrillation and supraventricular arrhythmias in patients with HFrEF and remote monitoring: preliminary data from the SAVE THE RHYTHM[J]. Eur Heart J, 2020, 41(Supplement_2).
[34]	Abumayyaleh M, Demmer J, Krack C, et al. Incidence of atrial and ventricular arrhythmias in obese patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan[J]. Diabetes Obes Metab, 2023, 25(10):2999-3011.
[35]	Dong Y, Zhai Z, Wang J, et al. Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation[J]. Sci Rep, 2023, 13(1):3140. doi: 10.1038/s41598-023-30349-w pmid: 36823222
[36]	Chen Q, Chen Y, Qin F, et al. Effect of sacubitril-valsartan on restoration and maintenance of sinus rhythm in patients with persistent atrial fibrillation[J]. Front Cardiovasc Med, 2022, 9:870203.
[37]	毕龙飞, 刘瑶, 余丹, 等. 沙库巴曲缬沙坦治疗消融术后心房颤动的疗效及安全性的Meta分析[J]. 医学新知, 2024, 34(8):916-926.
[38]	Zang X, Zhao Z, Chen K, et al. Evaluation of the efficacy of sacubitril/valsartan on radiofrequency ablation in patients with hypertension and persistent atrial fibrillation[J]. Cardiovasc Drugs Ther, 2025, 39(1):97-106.
[39]	Yang L, Zhang M, Hao Z, et al. Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients[J]. ESC Heart Fail, 2022, 9(4):2428-2434. doi: 10.1002/ehf2.13937 pmid: 35437929
[40]	格日勒, 吴云, 郭欣君, 等. 芪苈强心胶囊联合沙库巴曲缬沙坦钠治疗非射血分数减低型心力衰竭的疗效[J]. 疑难病杂志, 2021, 20(7):653-657.
[41]	Wang R, Ye H, Ma L, et al. Effect of sacubitril/valsartan on reducing the risk of arrhythmia: A systematic review and meta-analysis of randomized controlled trials[J]. Front Cardiovasc Med, 2022, 9:890481.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 41

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Shenghua. The predictive value of the metabolic score for insulin resistance in essential hypertension patients complicated by aortic arch calcification [J]. Clinical Focus, 2025, 40(7): 589-594.
[2]	. [J]. Clinical Focus, 2025, 40(7): 659-662.
[3]	Chen Min, Song Xinrong, Ma Bojian, Niu Huimin. Meta-analysis of the correlation between carotid plaque stability and ischemic stroke assessed by contrast-enhanced ultrasound [J]. Clinical Focus, 2025, 40(6): 492-497.
[4]	Cao Lihui, Huo Xianghui. Clinical diagnostic value of NT-proBNP and triglyceride-glucose index combined ith echocardiographic parameters in elderly patients with heart failure [J]. Clinical Focus, 2025, 40(6): 498-503.
[5]	Si Huili, Guo Shuang, Dong Haocheng, Li Shuren. Correlation of JP2 with atrial fibrillation in patients with essential hypertension [J]. Clinical Focus, 2025, 40(6): 504-508.
[6]	Liu Jia, Yang Fengyu, Guo Mengya, Wu Zhuowei, Zhang Hanwen, Wang Yixuan, Chen Chunhong, Zhang Fang. The safety and efficacy of low-dose rivaroxaban in elderly patients with renal insufficiency and non-valvular atrial fibrillation [J]. Clinical Focus, 2025, 40(6): 509-512.
[7]	. [J]. Clinical Focus, 2025, 40(6): 558-563.
[8]	. [J]. Clinical Focus, 2025, 40(6): 564-569.
[9]	Liu Ping, Yu Meng, Liu Mingxin, Li Wenfeng. Correlation of new inflammatory indicators in the complete blood count with major adverse cardiovascular events in patients with acute anterior wall ST-segment elevation myocardial infarction after percutaneous coronary intervention [J]. Clinical Focus, 2025, 40(5): 400-407.
[10]	Zhao Guangyan, Han Tuo, Liang Xiying, Wang Qian, Zhang Yan, Wang Congxia. Risk factors and predictive model for masked hypertension in young and middle-aged adults [J]. Clinical Focus, 2025, 40(3): 205-210.
[11]	Liu Shenghua. Correlation between serum uric acid levels and coronary artery calcification severity in patients with stable angina pectoris [J]. Clinical Focus, 2025, 40(3): 211-216.
[12]	. [J]. Clinical Focus, 2025, 40(3): 275-280.
[13]	Hu Songlin, Di Ya, Liu Canzhang, Yan Jie. Study on the relationship between platelet/lymphocyte ratio and coronary plaque characteristics in coronary heart disease patients combined with type 2 diabetes mellitus by virtual histology intravascular ultrasound [J]. Clinical Focus, 2025, 40(2): 117-121.
[14]	. [J]. Clinical Focus, 2025, 40(2): 172-179.
[15]	. [J]. Clinical Focus, 2025, 40(2): 180-184.